 |
|
Clinical and molecular characterization of Korean children with infantile and late-onset Pompe disease: 10 years of experience with enzyme replacement therapy at a single center
Min-Sun Kim (Kim MS), Ari Song (Song A), Minji Im (Im M), June Huh (Huh J), I-Seok Kang (Kang IS), Jinyoung Song (Song J), Aram Yang (Yang A), Jinsup Kim (Kim J), Eun-Kyung Kwon (Kwon EK), Eu-Jin Choi (Choi EJ), Sun-Ju Han (Han SJ), Hyung-Doo Park (Park HD), Sung Yoon Cho (Cho SY), Dong-Kyu Jin (Jin DK)
Clin Exp Pediatr. 2019;62(6):224-234. Published online 2018 Oct 4 DOI: https://doi.org/10.3345/kjp.2018.06968
|
|
Citations to this article as recorded by
 Two Approaches for a Genetic Analysis of Pompe Disease: A Literature Review of Patients with Pompe Disease and Analysis Based on Genomic Data from the General Population
Kyung-Sun Park
Children.2021; 8(7): 601. CrossRef Selective screening and molecular characteristics of Russian patients with Pompe disease
Kirill V. Savostyanov, Alexander A. Pushkov, Elena N. Basargina, Lyudmila M. Kuzenkova, Natalia N. Mazanova, Leila A. Gandaeva, Olga P. Zharova, Ekaterina E. Ryabova, Ilya S. Zhanin, Andrey P. Fisenko
L.O. Badalyan Neurological Journal.2021; 2(4): 203. CrossRef The Novel Compound Heterozygous Mutations of GAA Gene in Mainland Chinese Patient with Classic Infantile-Onset Pompe Disease
Jiaming Li, Yinghua Cui, Xin Wang, Qinglei Wang, Hongjun Wang, Bo Yan
International Heart Journal.2020; 61(1): 178. CrossRef Considerations for evaluating the effectiveness and long-term outcome of enzyme replacement therapy in Pompe disease
Chong Kun Cheon
Clinical and Experimental Pediatrics.2020; 63(1): 14. CrossRef
|